{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:58:07Z","timestamp":1761058687175},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,4,29]],"date-time":"2007-04-29T00:00:00Z","timestamp":1177804800000},"content-version":"vor","delay-in-days":3285,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[1998,5]]},"abstract":"<jats:p>The risk and safety of specific immunotherapy (SIT) has been the subject of many well\u2010designed studies since it was introduced. Most authors consider SIT an efficient and safe mode of treatment despite the occurrence of life\u2010threatening anaphylactic reactions. They emphasize the importance of a proper selection of patients as well as the requirement for highly qualified physicians to provide the treatment. Another problem associated with the safety of SIT is the potential enhancement of the synthesis of immune complexes after the treatment. SIT causes a decrease in allergen\u2010specific IgE which is slower in circulating immune complexes than in the serum. No data are available to show that SIT induces immune\u2010complex diseases, in either the immunologic or the clinical sense. As far as anaphylactic reactions are concerned, new alternative methods different from the conventional parenteral mode of delivery seem to be safe. Our increased understanding of the altered functions of the immune system justifies the assumption that the more specific the method of SIT administration, the more effective and safe it is.<\/jats:p>","DOI":"10.1111\/j.1398-9995.1998.tb04083.x","type":"journal-article","created":{"date-parts":[[2007,5,14]],"date-time":"2007-05-14T00:34:09Z","timestamp":1179102849000},"page":"473-476","source":"Crossref","is-referenced-by-count":7,"title":["Risk and safety of immunotherapy"],"prefix":"10.1111","volume":"53","author":[{"given":"B.","family":"Rogala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,4,29]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90265-8"},{"key":"e_1_2_1_3_2","first-page":"1","article-title":"Position paper on allergen immunotherapy","volume":"23","author":"BSACI Working Party","year":"1993","journal-title":"Clin Exp Allergy"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1994.tb00929.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)80183-7"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1993.tb04754.x"},{"key":"e_1_2_1_7_2","first-page":"185","article-title":"Specific immunotherapy 3 year follow\u2010up in asthmatic children","volume":"21","author":"Ferreira N","year":"1993","journal-title":"Allergol Immunopathol (Madr)"},{"key":"e_1_2_1_8_2","first-page":"250","article-title":"Safety of specific immunotherapy: a retrospective study","volume":"4","author":"Luigi A","year":"1994","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.2500\/108854193778774001"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.10.010"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(95)70146-X"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90064-7"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)80119-9"},{"key":"e_1_2_1_14_2","first-page":"293","article-title":"desensitizing vaccines","author":"Committee on the Safety of Medicines (CSM) update","year":"1986","journal-title":"BMJ"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(87)80164-1"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.2500\/108854194778816562"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199410010-00002"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80091-0"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.2500\/108854194778816553"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1993.tb00743.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1977.tb01438.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(79)90123-4"},{"key":"e_1_2_1_23_2","first-page":"11","volume-title":"Dust mite allergens and asthma","author":"Platts\u2010Mills TAE","year":"1991"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(79)90122-2"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1995.tb01019.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(93)90166-D"},{"key":"e_1_2_1_27_2","first-page":"81","article-title":"Alternative routes for allergen\u2010specific immunotherapy","volume":"6","author":"Passalacqua G","year":"1996","journal-title":"J Invest Allergol Clin Immunol"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.4049\/jimmunol.151.9.4773","article-title":"CDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen: characterization of the recombinant pHI pV allergen","volume":"151","author":"Vrtala S","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_1_29_2","first-page":"165","article-title":"Allergen\u2010specific therapy in type I allergy: new concepts based on recombinant allergens","volume":"6","author":"Valenta R","year":"1994","journal-title":"Allergy Clin Immunol News"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92963-I"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1991.tb00596.x"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-540"},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","article-title":"Humanization of an antibody directed against IgE","volume":"151","author":"Presta L","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237010"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.1998.tb04083.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.1998.tb04083.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T16:21:26Z","timestamp":1695831686000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.1998.tb04083.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,5]]}},"alternative-id":["10.1111\/j.1398-9995.1998.tb04083.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.1998.tb04083.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,5]]}}}